Steven D. Colan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Steven D. Colan has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Steven E. Lipshultz
Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY (S.E.L.).
12 shared publications - Jeffrey A. Towbin
Department of Pediatrics, University of Tennessee Health Science Center, Le Bonheur Children’s Hospital, Memphis (J.A.T.).
7 shared publications - James D. Wilkinson
Department of Pediatrics Vanderbilt School of Medicine Nashville Tennessee USA
4 shared publications Stuart R Lipsitz
University of Rochester, Rochester
3 shared publicationsAdrian M Moran
The Department of Cardiology, Maine Medical Center, Portland, Maine, USA; and the Department of Pediatrics, University of Vermont, Burlington, Vermont, USA
2 shared publicationsE. John Orav
From the Children’s Hospital, Harvard Medical School, Boston, Mass (S.D.C., J.M., G.F.C.); Holtz Children’s Hospital, University of Miami, Miami, Fla (S.E.L.); New England Research Institutes, Watertown, Mass (A.M.L., L.A.S.); Genzyme Corporation, Cambridge, Mass (G.F.C.); Albany Medical College, Albany, NY (P.R.L.); Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (E.J.O.); and Texas Children’s Hospital, Baylor College of Medicine, Houston (J.A.T.).
2 shared publications
Latest Publications
- 27 November 2018
- Published by Springer Nature
- p. 121-144
Pediatric Diagnosis and Management
- 1 January 2018
- Published by Elsevier
List of Contributors
- 1 March 2016
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 40, 1
Progress in Pediatric Cardiology
- 1 March 2016
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 40, 1
Progress in Pediatric Cardiology
- 1 July 2015
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 39 (1) , 1
Progress in Pediatric Cardiology
- 1 July 2015
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 39 (1) , 1
Progress in Pediatric Cardiology
- 1 March 2015
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 25 (S2) , 154-159
Review of the International Society for Heart and Lung Transplantation Practice guidelines for management of heart failure in children
In 2004, practice guidelines for the management of heart failure in children by Rosenthal and colleagues were published in conjunction with the International Society for Heart and Lung Transplantation. These guidelines have not been updated or reviewed since that time. In general, there has been considerable controversy as to the utility and purpose of clinical practice guidelines, but there is general recognition that the relentless progress of medicine leads to the progressive irrelevance of clinical practice guidelines that do not undergo periodic review and updating. Paediatrics and paediatric cardiology, in particular, have had comparatively minimal participation in the clinical practice guidelines realm. As a result, most clinical practice guidelines either specifically exclude paediatrics from consideration, as has been the case for the guidelines related to cardiac failure in adults, or else involve clinical practice guidelines committees that include one or two paediatric cardiologists and produce guidelines that cannot reasonably be considered a consensus paediatric opinion. These circumstances raise a legitimate question as to whether the International Society for Heart and Lung Transplantation paediatric heart failure guidelines should be re-reviewed.The time, effort, and expense involved in producing clinical practice guidelines should be considered before recommending an update to the International Society for Heart and Lung Transplantation Paediatric Heart Failure guidelines. There are specific areas of rapid change in the evaluation and management of heart failure in children that are undoubtedly worthy of updating. These domains include areas such as use of serum and imaging biomarkers, wearable and implantable monitoring devices, and acute heart failure management and mechanical circulatory support. At the time the International Society for Heart and Lung Transplantation guidelines were published, echocardiographic tissue Doppler, 3 dimensional imaging, and strain and strain rate were either novel or non-existent and have now moved into the main stream. Cardiac magnetic resonance imaging (MRI) had very limited availability, and since that time imaging and assessment of myocardial iron content, delayed gadolinium enhancement, and extracellular volume have moved into the mainstream. The only devices discussed in the International Society for Heart and Lung Transplantation guidelines were extracorporeal membrane oxygenators, pacemakers, and defibrillators. Since that time, ventricular assist devices have become mainstream. Despite the relative lack of randomised controlled trials in paediatric heart failure, advances continue to occur. These advances warrant implementation of an update and review process, something that is best done under the auspices of the national and international cardiology societies. A joint activity that includes the International Society for Heart and Lung Transplantation, American College of Cardiology/American Heart Association, the Association for European Paediatric and Congenital Cardiology (AEPC), European Society of Cardiology, Canadian Cardiovascular Society, and others will have more credibility than independent efforts by any of these organisations.
- 1 March 2015
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 25 (S2) , 154-159
Review of the International Society for Heart and Lung Transplantation Practice guidelines for management of heart failure in children
In 2004, practice guidelines for the management of heart failure in children by Rosenthal and colleagues were published in conjunction with the International Society for Heart and Lung Transplantation. These guidelines have not been updated or reviewed since that time. In general, there has been considerable controversy as to the utility and purpose of clinical practice guidelines, but there is general recognition that the relentless progress of medicine leads to the progressive irrelevance of clinical practice guidelines that do not undergo periodic review and updating. Paediatrics and paediatric cardiology, in particular, have had comparatively minimal participation in the clinical practice guidelines realm. As a result, most clinical practice guidelines either specifically exclude paediatrics from consideration, as has been the case for the guidelines related to cardiac failure in adults, or else involve clinical practice guidelines committees that include one or two paediatric cardiologists and produce guidelines that cannot reasonably be considered a consensus paediatric opinion. These circumstances raise a legitimate question as to whether the International Society for Heart and Lung Transplantation paediatric heart failure guidelines should be re-reviewed.The time, effort, and expense involved in producing clinical practice guidelines should be considered before recommending an update to the International Society for Heart and Lung Transplantation Paediatric Heart Failure guidelines. There are specific areas of rapid change in the evaluation and management of heart failure in children that are undoubtedly worthy of updating. These domains include areas such as use of serum and imaging biomarkers, wearable and implantable monitoring devices, and acute heart failure management and mechanical circulatory support. At the time the International Society for Heart and Lung Transplantation guidelines were published, echocardiographic tissue Doppler, 3 dimensional imaging, and strain and strain rate were either novel or non-existent and have now moved into the main stream. Cardiac magnetic resonance imaging (MRI) had very limited availability, and since that time imaging and assessment of myocardial iron content, delayed gadolinium enhancement, and extracellular volume have moved into the mainstream. The only devices discussed in the International Society for Heart and Lung Transplantation guidelines were extracorporeal membrane oxygenators, pacemakers, and defibrillators. Since that time, ventricular assist devices have become mainstream. Despite the relative lack of randomised controlled trials in paediatric heart failure, advances continue to occur. These advances warrant implementation of an update and review process, something that is best done under the auspices of the national and international cardiology societies. A joint activity that includes the International Society for Heart and Lung Transplantation, American College of Cardiology/American Heart Association, the Association for European Paediatric and Congenital Cardiology (AEPC), European Society of Cardiology, Canadian Cardiovascular Society, and others will have more credibility than independent efforts by any of these organisations.
- 1 December 2014
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 37 (1-2)
Progress in Pediatric Cardiology
- 1 December 2014
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 37 (1-2)
Progress in Pediatric Cardiology
- 1 October 2014
- Published by Springer Nature
- p. 107-122
Pediatric Diagnosis and Management
- 1 September 2014
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 36 (1-2) , 7-10
Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer
- 1 September 2014
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 36 (1-2) , 7-10
Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer